STADA’s Strong Growth Journey Continues in 2025

Biosimilars and Innovative Medicines Growth Takes Specialty over €1 billion

Specialty revenues climbed by 17% on an adjusted, constant-currency basis, now accounting for almost one quarter of Group revenues. The segment thus maintained its double-digit growth trajectory of recent years.

Building on proven partnerships with developers across Europe and China, in combination with a strong marketing and sales platform across all European markets, biosimilars sales advanced in double digits. Key drivers included the continued growth of Uzpruvo (ustekinumab), which captured top positions in all of the more than 20 markets where the brand has been launched, as well as further growth from the existing biosimilars portfolio across a broad range of therapeutic areas such as bone health, immunology and oncology. Five biosimilar launches are scheduled during 2026, including golimumab and tocilizumab, as STADA builds on its position as a biosimilars leader in Europe with a broad portfolio consisting of 11 approved products, along with geographic presence and patient outreach in Europe that few competitors can match.

Innovative medicines made significant progress, expanding patient access to best-in-class treatments for serious conditions in nephrology and neurology.

High double-digit growth for Kinpeygo was driven by successful expansion of the label, allowing for use in a larger cohort of patients with the rare kidney disease IgAN. Following launches in 19 European countries to date, Kinpeygo’s uptake was further accelerated by endorsement in the KDIGO clinical treatment guidelines as well as real-world data on safety and efficacy. Launches in additional markets are planned for 2026 and beyond.

In neurology, launches of the Lecigon intestinal infusion pump in additional countries including France and the UK expanded access for people living with advanced Parkinson’s disease. After enjoying broad success in Europe with apomorphine, a subcutaneous infusion device for treatment of moderate-to-severe Parkinson’s patients, STADA has launched the therapy, under the brand name ONAPGO, in the sizable US market with its partner Supernus. In addition, STADA during 2025 expanded its Specialty oncology portfolio by launching nilotinib and paclitaxel albumin.

Rivaroxaban leads above-market Generics growth

2025 Generics revenues advanced by 5% (adj cc) as the segment continued to outperform the market in Europe. Generics growth was driven in large part by a successful rivaroxaban launch achieved through a strong intellectual-property position. Successful launches and commercial synergy enhanced STADA’s top-three retail generics market ranking in countries like Germany, Italy, Spain, Belgium, Ireland, the Nordics, Serbia and Switzerland. Performance in Generics was further fueled by cardiovascular medicines, in particular apixaban, dabigatran and ticagrelor, as well as from several statins. STADA also benefited from filling in gaps in local Generics portfolios, such as with enoxaparin in Belgium, or the Proxor (beclomethasone/formoterol) inhaler in the UK.

Consumer Healthcare grows with local hero brands despite soft cough/cold season

Despite a relatively low incidence of coughs and colds in key markets, the Consumer Healthcare segment delivered a solid performance in 2025 with 2% (adj cc) revenues growth. Outside the cough & cold category, STADA delivered mid-single-digit growth, based on continued strong performance of its industry-leading number of top-ranked brands across various country-categories such as: Nizoral, Levomecol and Cetraben in dermatology; Elotrans and Protectis in gastrointestinal; and Eunova, Walmark and Natures Aid in vitamins, minerals and supplements. The segment continued to make progress with several significant launches and line extensions including extensions to the Nizoral scalp-care brand, including Nizoral Care Conditioner and Nizoral Cream. STADA’s top brand in the UK, Zoflora, benefitted from line extensions in the home hygiene and disinfectants sectors.

Reflecting and anticipating consumer trends, STADA nearly doubled its eCommerce sales between 2022 and 2025, with more than half of the Group’s media budget allocated to digital channels. STADA continues to accelerate eCommerce growth by expanding geographically and adopting an omnichannel approach to engage consumers on platforms like Google, TikTok and Instagram, as well as making targeted use of AI technologies.

Evaluating acquisition targets worldwide

“To drive further Consumer Healthcare growth,” revealed Goldschmidt, “we are actively evaluating acquisition targets around the world to enhance our broad healthcare platform, on top of our strong internal pipeline. At the same time, we continue to capitalize on opportunities to expand our brand portfolio in the fastest-growing categories such as dermatology, preventive health and wellness.”

Strong build-out of future pipeline

“Our oncology pipeline is highly promising, containing molecules such as enzalutamide and ruxolitinib, and we have apixaban and edoxaban to complement our ongoing launch of rivaroxaban in the cardiovascular category.”

“Our biosimilar partnerships are set to deliver imminent entry into limited competition markets such as golimumab and tocilizumab, building on our denosumab launch in Europe at the end of 2025,” Goldschmidt continued. “Through the 110 business development and licensing (BD&L) deals we signed in 2025, on top of our extensive development and licensing partnership network, we have built a highly-promising pipeline for years to come.”

“We are fully prepared with a well-stocked development pipeline and strategy to address the GLP-1 loss-of-exclusivity opportunities in both diabetes and weight-loss, targeting blockbuster brands such as semaglutide-based Ozempic and Wegovy, and liragutide-based Saxenda and Victoza. On top of this, the SGLT-2 inhibitor empagliflozin is a key pipeline asset in diabetes.”

Culture Drives Performance

Highlighting STADA’s recent re-certification as a Top Employer Europe, as well as 88% employee participation in the latest employee survey with four in five proud to work for STADA, far outperforming industry norms, Goldschmidt concluded: “Beyond all operations and pipeline opportunities, what keeps STADA performing ahead of the market is our unique One STADA spirit and growth culture. The outstanding dedication of our almost 12,000 employees around the world, more than half of which work in our TechOps team ensuring reliable supplies of medicines to patients, is the foundation of our continued growth journey and our devotion to ‘Caring for People’s Health as a Trusted Partner’.”

Strong year for STADA in the UK

“STADA UK continues to outperform the market across many of our core categories within healthcare where are energised by the growth prospects in 2026 and beyond,” said Craig Shaw, UK General Manager, who joined the business last October. The UK is STADA’s second-largest Consumer Healthcare market by sales, and provides a range of further healthcare solutions across its Specialty & Generics business.

Shaw added: “Digital marketing and ecommerce are continuing to grow at double-digit levels as we ensure our products are within arm’s reach of our customers’ needs. Today, as we publish our results, our Nizoral Anti-Dandruff Treatment Shampoo is the number one ranked Shampoo & Conditioner product on Amazon, thanks to its clinically proven formula that treats dandruff from the very first wash. Covonia, our cough and cold medicine, is gaining market share following our winter ‘The Bull is Back’ multi-media campaign hitting broadcast TV during the key winter season.

"With our Britannia neurology offering we are dedicated to improving the lives of people with long-term conditions, and providing important support for their families, caregivers, and medical teams. Whilst our Natures Aid Vitamins, Minerals & Supplements business offers a full range of self-care solutions for infants to older people, ensuring STADA is well placed to provide a broad treatment portfolio for a wide range of healthcare needs in the UK"

. In March Natures Aid launched the UK’s first range for Bluey vitamins to help support everyday health, immune & bone health in children from aged 3. The range is being sold through Boots, Morrisons, Holland & Barrett and key online retailers such as Ocado & Amazon.

STADA Thornton Ross also continues to play a leading role as a supplier of dermatology creams to the NHS. In the prescription-only sector, the company continues to offer a range of therapeutic options with respiratory inhalers, an ustekinumab biosimilar in immunology, and an orphan medicine for rare and debilitating kidney disease IgA-Nephropathy (IgAN).

The success story also reflects STADA’s growth as a manufacturing powerhouse in the UK. Around 68 million products were manufactured at STADA Thornton & Ross’s Linthwaite, West Yorks site, including more than 20 million bottles of Zoflora concentrate. The Natures Aid site, at Kirkham, Lancs, produced an impressive 6.5m packs of vitamins and supplements.

STADA also continues to play a leading role as a supplier of dermatology creams to the NHS. In the prescription-only sector, the company continues to offer a range of therapeutic options with respiratory inhalers, an ustekinumab biosimilar in immunology, and an orphan medicine for rare and debilitating kidney disease IgA-Nephropathy (IgAN). 

About STADA Arzneimittel AG 

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2025, STADA achieved group sales of € 4,296 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 961 million. As of 31 December 2025, STADA employed 11,749 people worldwide.

Additional information for journalists

STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
E-Mail: [email protected]
Or visit us via our website at https://www.stada.com/media/newsroom
Follow @stadaGroup on LinkedIn

Additional information for capital market participants

STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: [email protected]
Or visit us via our website at https://www.stada.com/investor-relations/

 

>